Jugular foramen tumors are uncommon cranial base lesions that cause difficulties not only in diagnosis but in treatment as well. Paraganglioma is the most common tumor involving this region. Other common tumors arising in the jugular foramen are meningiomas, schwannomas and chondrosarcomas. Metastatic involvement of this location is rare. We present a case of metastasis of lung adenocarcinoma in jugular foramen presented with cranial neuropathy. Although it is rare, metastasis of a systemic malignancy should always be considered in the differential diagnosis of a mass involving jugular foramen.
BACKGROUND
Jugular foramen tumors are rare cranial base lesions which cause difficulties not only in diagnosis but in treatment as well. Paraganglioma is the most common tumor involving this region. Other common tumors arising in the jugular foramen are meningiomas, schwannomas, and chondrosarcomas. Metastatic involvement of this location is rare [1] . We report a case of a lung cancer metastasis in jugular foramen who presented with a cranial neuropathy.
CASE REPORT
A 56-year-old woman who has been under the follow-up for a surgically treated primary lung adenocarcinoma for 6 years, admitted to the Department of Otorhinolaryngology suffering from hoarseness and a pharyngeal pain of 1 week. On examination, she was noted to have a right vocal cord paresis. Computerized tomography (CT) of thorax showed no remarkable change compared to her prior examination. CT of neck revealed a right vocal cord paresis (Figure 1) . Contrast-enhanced neck CT demonstrated a well defined, diffusely enhancing skull base mass involving the right jugular foramen and extending extracranially (Figure 2) . The jugular spine was well delineated and no evidence of bone erosion in either the right jugular foramen or the neighboring bone structures was noted. The right jugular vein was deplaced posterolaterally (Figure 3) . On magnetic resonance imaging (MRI), the mass was; 3.3x1.4x1.1 cm on size, showed high signal on T2 weighted images and was diffusely enhancing on gadolinium enhanced sequences. There was no evidence of vascular infiltration on MRI ( Figure  4) . On 18-fluoro deoxyglucose (FDG) positron emission tomography (PET) scan, the mass revealed high positive FDG uptake and diagnosed as metastasis. Chemotherapy in conjunction with radiation therapy was planned for the treatment of the patient. She rejected chemotherapy. The patient was then transferred to the Department of Radiation Oncology and an external-beam radiation therapy was planned.
DISCUSSION
Metastatic involvement of cranial base is seen in only 4% of patients with systemic malignancies. The breast, lung, and prostate malignancies are shown to have a tendency to metastasize to the structures of cranial base [2] . Being only 3.5% of all cranial base metastases, jugular foramen involvement is very uncommon among the other cranial base structures [3] .
The presenting symptoms of jugular foramen metastases are; hoarseness, dysphagia, and pain in the occipital and pharyngeal regions, as in the present case. Neurological examination reveals involvement of the last four cranial nerves (IX-XII), occasionally associated with Horner's syndrome [2] . A similar clinical presentation may be the result of a large number of lesions, so the differential diagnosis of a jugular foramen tumor may be very difficult. This is true especially in the cases without a previous cancer diagnosis. Radiological assessment plays a critical role in both accurate diagnosis and management [4] [5] [6] [7] [8] . The identification of most lesions can be made by combination of CT and MRI [9] .
The evaluation of bone structures in cases of meningiomas, aneurysmatic bone cysts, and condrosarcomas is made by CT. It is also the choice of imaging modality in demonstrating hyperostosis and tumor calcification. Gadolinium enhanced MRI clearly demonstrates the morphology and extension of the tumor, its vascularization and its relationship with other structures. If needed, MR angiography and/or digital subtraction angiography (DSA) may be performed to show the tumor vascularization and venous circulation. Paragangliomas are highly vascularized lesions that show heterogeneous contrast enhancement. Schwannomas are also strongly enhancing masses which present a regular contour, cystic appearance in some cases, and occasionally "hour glass" shape. Meningiomas may show dural tail, hyperostosis, and characteristic "sunburst" appearance following gadolinium administration. Chondrosarcomas are destructive masses with irregulary contours, showing heterogeneous contrast enhancement [1, 9] . Metastases at the jugular foramen and at other regions of the skull base classically present as lytic lesions [9] [10] [11] [12] [13] . In the present case, imaging findings of the mass were not typical of a metastasis. There was neither bone destruction nor soft tissue infiltration. In contrast to most of the previously reported cases, it was a homogeneously enhancing, well defined, lobulated mass which is consistent with a benign lesion rather than a metastasis. However, sudden onset of the symptoms and the known primary lung malignancy of the patient were taken into account and the final diagnosis was a metastasis. In the cases of jugular foramen involvement, surgical resection has the potential risks of; cerebrovascular morbidity, meningitis, cerebrospinal fluid leakage, and additional cranial nerve deficits. Conformal fractioned radiation therapy to the region of involvement and control of the systemic malignancy with chemotherapy are shown to be the best choices of treatment for most cases [2] . For primary management or for the treatment of residual and recurrent skull base metastases following surgery or radiotherapy, stereotactic radiosurgery is a minimally invasive palliative option. The prognosis for skull base metastases is poor, with a median survival of about 1 year [11] .
Although it is rare, metastasis of a systemic malignancy should always be considered in the differential diagnosis of a mass involving jugular foramen.
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